FDAsafety guidance66% confidence
Wizcure Pharmaa Private Limited - 726378 - 06/24/2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Novitium Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pain Management · NSAID
- Sub-indication
- Pain
Related signal: FDA Accepts Supplement for Naproxen by Novitium Pharma